Cromos Pharma commences a pivotal multicountry clinical trial of OT-101 in patients with advanced pancreatic cancer.

Cromos Pharma commences a pivotal multicountry clinical trial of OT-101 in patients with advanced pancreatic cancer

Cromos Pharma is thrilled to announce the commencement of a pivotal trial, focused on the investigation of OT-101, a collaborative effort between Oncotelic  Therapeutics and Sapu Bioscience, in individuals suffering from advanced and unresectable or metastatic pancreatic cancer. With this ambitious multicountry endeavor, Cromos Pharma’s aspiration is to deliver a long-awaited enhancement in survival outcomes for patients afflicted by this devastating illness. 

Please read a press release here

If you have any questions or want to find out more about how Cromos Pharma can support your next clinical trial, please contact us by emailing inquiry@cromospharma.com.

 

Schedule a meeting

We are excited to connect with you, understand your goals, and explore how we can support your needs.

Contact us

OUR PUBLICATIONS